Fundraising Fox
/Companies
Sign in

Aqemia

Founded 2019 · 84 employees on LinkedIn · 6 known investors

Find your way into Aqemia

Each arrow is one introduction. Sign up to fill in the first one.

208 people can intro you to Maximilien

Ask Nicolas Autret to introduce you to Maximilien Levesque

You →Nicolas · together at Aqemia →Maximilien

Sign up to find every way you can get introduced to Aqemia

  • Your email: who you already know at Aqemia, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Aqemia team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Aqemia applies atomic-scale physics and generative AI to accelerate drug discovery and molecular design, enabling faster identification of innovative medicines for unmet therapeutic needs. The company uses proprietary deep physics algorithms and machine learning to predict drug properties and design novel molecules, serving pharmaceutical and biotech organizations.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Aqemia was founded in 2019 by Maximilien Levesque and Emmanuelle Martiano-Rolland.

MLMaximilien Levesque
Maximilien LevesquePhD, Prof., CEO and Co-FounderMaximilien Levesque holds a PhD in quantum mechanics and spent over a decade in drug discovery research, including six years as a research group leader at École normale supérieure Paris developing computational methods for molecular design. He is CEO and Co-Founder of Aqemia, which applies physics-based AI to accelerate pharmaceutical research and drug discovery.
EM
Emmanuelle Martiano-RollandCOO and Co-Founder

Investors · 6

Elaialisted by ElaiaParis · $108K – $1.6M

How we know: Elaia's portfolio page · a partner's Signal profile · funding news · biopharmatrend.com · the VCSheet dataset · Not right? Tell us

PSL Innovation Fundlisted by PSL Innovation FundParis

How we know: PSL Innovation Fund's portfolio page · Not right? Tell us

BpifrancereportedParis, Ile-De-France · $270K

How we know: funding news · biopharmatrend.com · Not right? Tell us

EurazeoreportedParis

How we know: funding news · biopharmatrend.com · Not right? Tell us

Also in the syndicate · 1

Wendel Growth

Funding

SEC filings, press & company announcements

$38M disclosed across 1 of 3 rounds · 2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Aqemia raises $38M to find new drugs by meshing theoretical physics with GenAI | TechCrunchtechcrunch.com · Dec 2024Aqemia Raises $38M in Fundingfinsmes.com · Dec 2024Aqemia Raises Additional €30M in Series Afinsmes.com · Jan 2024

Frequently asked questions

What does Aqemia do?
Aqemia applies atomic-scale physics and generative AI to accelerate drug discovery and molecular design, enabling faster identification of innovative medicines for unmet therapeutic needs. The company uses proprietary deep physics algorithms and machine learning to predict drug properties and design novel molecules, serving pharmaceutical and biotech organizations.
Who founded Aqemia?
Aqemia was founded by Maximilien Levesque, Emmanuelle Martiano-Rolland in 2019.
Who are Aqemia's investors?
Aqemia's investors include Cathay Innovation, Elaia, PSL Innovation Fund, Bpifrance, Eurazeo.
How much funding has Aqemia raised?
Aqemia has disclosed $38M raised across 1 of its 3 known rounds.